SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

EU slaps a fine of euro 10.32 million on Ranbaxy Labs for delaying the entry of cheaper drugs

20 Jun 2013 Evaluate

The European antitrust regulators, on Wednesday, slapped a fine of 146 million euro on nine pharma companies, including Ranbaxy Laboratories, for blocking the market entry of cheaper generic versions of Danish company Lundbeck’s branded citalopram, a blockbuster anti-depressant. While, the European Commission fined euro 93.8 million on Danish pharmaceutical company Lundbeck, a fine of euro 10.32 million was imposed on Ranbaxy Laboratories.

The penalty follows a 2009 report by the European Commission on the pharmaceutical sector, which pointed at 'pay-for-delay' agreements between companies, leading to consumers paying as much as 20 percent more for their medicines. Pay-for-delay agreements involve brand-name firms paying generic companies not to market rival versions of their medicine. These agreements violated the EU antitrust rules that prohibit anticompetitive agreements (Article 101 of the Treaty on the Functioning of the European Union -TFEU).

Further, country’s largest pharmaceutical company, Ranbaxy now plans to appeal to the EU General Court in Luxembourg, Europe's second-highest, after being fined 10.3 million euros.

Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×